Search Results - therapeutics+%3e+oncology

114 Results

Sort By:

Integrated Molecular and Lipidomic Analysis of Glioma Tumors Identifies Therapeutic Vulnerabilites (UCLA Case No. 2023-210)

UCLA researchers in the Department of Molecular and Medical Pharmacology have uncovered a novel therapeutic target for Glioblastoma leveraging an extensive lipidomic and transcriptomic database. BACKGROUND: Glioblastoma (GBM) is a fast-growing and aggressive brain tumor. The National Brain Tumor Society predicted that over 14,000 people in the United...

Published: 3/11/2024 | Inventor(s): David Nathanson

Keywords(s): Brain cancer, Brain Tumor, cancer target, cell death, ferroptosis, Glioblastoma, lipidomics

Category(s): Therapeutics > Oncology

Novel Anti-mesothelin CAR for Use in Engineered Cell Therapies (UCLA Case No. 2023-281)

UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have developed a nanobody-based CAR T cell platform with increased stability and cross-immunogenicity between human and mouse antigens. BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy makes use of reengineered T cells to target and clear cancer cells....

Published: 3/6/2024 | Inventor(s): Yvonne Chen

Keywords(s): Cancer, CAR-T cell platform, CAR-T cell therapy, cell engineering, Immunotherapy, Mesothelin, nanobody, Nanoparticle

Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

Synthetic Viscoelastic Activating Cells (SynVACs) for T cell engineering (UCLA Case No. 2023-190)

UCLA researchers in the Department of Bioengineering have developed a novel microfluidic device that produces synthetic viscoelastic cells for efficacious therapeutic T cell activation. BACKGROUND: T cell-based therapies, such as the chimeric antigen receptor (CAR) T cell therapy, represents a significant advancement in cancer treatment, particularly...

Published: 3/6/2024 | Inventor(s): Zeyang Liu, Song Li, Lili Yang, Yan-Ruide Li

Keywords(s): CAR-T cell therapy, Synthetic antigen presenting cells (SynVACs), T Cell, T cell based therapy, T-cell activation, T-cell engineering, t-cells

Category(s): Therapeutics > Oncology

Biomaterial-Based Vaccine Booster to Enhance Long-Term Immunity (UCLA Case No. 2021-170)

UCLA researchers have developed injectable, cell-free, and biomaterial-based microparticles that can engage with tissue resident immune cells and enhance long-term immunity. It is the first biomaterial-based, targeted approach to induce T memory stem cells (TMSCs) in vivo. The approach was demonstrated for SARS-CoV-2 but can be used for any vaccine....

Published: 2/26/2024 | Inventor(s): Mohammad Hasani-Sadrabadi, Song Li, Manish Butte

Keywords(s): aAPCs, Aging, artificial presenting cells, cytokines, elderly, immunosenescence, microparticles, platform technology, SARS-CoV-2, T memory stem cells, TMSCs, Vaccines

Category(s): Therapeutics > Infectious Diseases, Therapeutics > Oncology

Targeting Prostate Cancer with a Novel T-Cell Receptor and Tissue-Specific Cancer Antigens for Improved Immune Response (UCLA Case No. 2022-070)

Researchers from UCLA’s Department of Microbiology, Immunology, & Molecular Genetics (MIMG), and the department of Molecular and Medical Pharmacology have identified a set of tissue-specific antigens which have been used to isolate and characterize a group of novel T-cell receptors (TCRs) which target prostate cancer specifically. Furthermore,...

Published: 2/26/2024 | Inventor(s): Owen Witte, Zhiyuan Mao, Jami Witte, Pavlo Nesterenko, John Lee

Keywords(s): Cancer, cancer antigen, Peptide, peptides, prostate cancer, protein, t-cells

Category(s): Therapeutics, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy

New Fusion Molecule Based on Novel TAA Variant (UCLA Case No. 2007-217)

BACKGROUND: Renal cell carcinoma (RCC) affects approximately 39,000 Americans and causes an estimated 13,000 deaths per year. Metastatic RCC poses a therapeutic challenge because of its resistance to conventional modes of therapy. Approximately one third of RCC patients will present at the metastatic stage and one third of patients with localized disease...

Published: 2/16/2024 | Inventor(s): Arie Belldegrun, Zhenhua Li

Keywords(s): Cancer, Immunotherapy, Renal, Renal cell carcinoma, renal diseases

Category(s): Therapeutics > Immunology And Immunotherapy, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology, Therapeutics > Renal

Targeting the Intrinsic Apoptotic Machinery in Glioblastoma Multiforme (GBM) (UCLA Case No. 2020-446)

UCLA researchers in the Department of Molecular and Medical Pharmacology identified the mechanisms of apoptotic resistance in glioblastoma multiforme (GBM) and developed a novel therapy to treat GBM. BACKGROUND: Glioblastoma (GBM) is the most aggressive form of brain tumor. Therapeutic options for GBM are limited and suboptimal. Treatment usually...

Published: 2/16/2024 | Inventor(s): David Nathanson

Keywords(s): anti-apoptotic inhibitor, Anti-apoptotic pathway, Apoptosis, Brain Tumor, Glioblastoma, irradiation, p53, temozolomide

Category(s): Therapeutics > Oncology

Intelligent Stent System for Chronic On-Demand Drug Delivery (Case No. 2021-069)

Summary: UCLA researchers in the Department of Neurology have developed an intelligent stent system for chronic on-demand drug delivery, addressing the challenge of the blood-brain barrier hindering drug therapy in the central nervous system. Background: The blood-brain barrier poses a significant obstacle to effective drug delivery to the central...

Published: 2/26/2024 | Inventor(s): Jose Morales, Haotian Lu, Huachen Cui, Xiaoyu (Rayne) Zheng

Keywords(s): blood flow management, blood-brain barrier, Drug, Drug Delivery, Drug monitoring, Invasiveness Of Surgical Procedures, MEMS, minimally invasive device, minimally invasive drug delivery systems, neural signals, neural stimulation, Neurocognitive, Neurodegeneration, neurological disorders, Neurology, neuro-oncology, Neuropathology, Neurosurgery, non-invasive, non-invasive drug monitoring, on-demand drug delivery, Pharmaceutical Drug, piezoelectric ultrasound transducers

Category(s): Platforms, Platforms > Drug Delivery, Medical Devices, Therapeutics, Therapeutics > CNS and Neurology, Therapeutics > Oncology, Therapeutics > Musculoskeletal Disease

Targeted Epigenetic Editing as Novel Therapy for Malignant Glioma (UCLA Case No. 2023-047)

UCLA Researchers in the Department of Neurology/Neuro-Oncology and the David Geffen School of Medicine have developed methods for the Cas9-CRISPR mediated epigenetic targeting of malignant glioma, and which results in enhanced chemosensitivity to standard chemotherapeutic agents. BACKGROUND: Malignant gliomas are aggressive brain tumors originating...

Published: 1/17/2024 | Inventor(s): Serendipity Zapanta Rinonos, Albert Lai

Keywords(s): Brain, Cancer, Cancer stem cells, Chemotherapy, Combination therapy, CRISPR, CRISPR-Cas9, Epigenetics, GBM, Glioma

Category(s): Therapeutics > Oncology, Therapeutics > CNS and Neurology

Combination of Supercharged NK with Supercharged Gamma Delta T Cells and Supercharged CD8+ T Cells and Super Charged iNKT Cells Should Eliminate Both (UCLA Case No. 2022-322)

SUMMARY: Researchers at UCLA’s School of Dentistry have developed methods and protocols for culturing and priming various immune cells into a “supercharged” phenotype. The studied cell types include NK and iNKT cells, gamma delta T cells, and CD8+ T cells. When deployed in combination, these supercharged cells were found to eliminate...

Published: 7/19/2023 | Inventor(s): Anahid Jewett

Keywords(s):

Category(s): Therapeutics, Therapeutics > Oncology, Therapeutics > Oncology > Oncology Immunotherapy

1 2 3 4 5 6 7 8 9 10 ...